Hikma Pharmaceuticals (HIK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,966.00p
   
  • Change Today:
      8.00p
  • 52 Week High: 2,205.00
  • 52 Week Low: 1,722.00
  • Currency: UK Pounds
  • Shares Issued: 221.89m
  • Volume: 14,887
  • Market Cap: £4,362.26m
  • RiskGrade: 125

ShareCast News

Hikma appoints Riad Mishlawi as CEO 12-Apr-2023 ShareCast
Berenberg raises target price on Hikma Pharmaceu... 27-Feb-2023 ShareCast
Competition in generics sees Hikma Pharmaceutica... 23-Feb-2023 ShareCast
Director dealings: Hikma Pharmaceuticals directo... 18-Jan-2023 ShareCast
Hikma launches generic narcolepsy solution in US 03-Jan-2023 ShareCast
RBC Capital Markets starts Hikma at 'outperform' 06-Dec-2022 ShareCast
Credit Suisse initiates coverage of Hikma at 'ou... 15-Nov-2022 ShareCast
Hikma reiterates FY guidance amid 'strong moment... 03-Nov-2022 ShareCast
Berenberg initiates coverage on Hikma Pharmaceut... 04-Oct-2022 ShareCast
Barclays downgrades Hikma to 'equalweight' on Ge... 05-Aug-2022 ShareCast
Hikma cuts guidance on lagging generics business 04-Aug-2022 ShareCast
Hikma's Siggi Olafsson stands down as CEO 24-May-2022 ShareCast
Hikma cuts 2022 generics guidance due to drug la... 05-May-2022 ShareCast
Hikma shares fall as generics unit faces headwinds 29-Apr-2022 ShareCast
Hikma gets preliminary approval from US FTC for ... 20-Apr-2022 ShareCast
Hikma Pharmaceutical delivers year of 'solid gro... 24-Feb-2022 ShareCast
Hikma buys Teligent Canadian assets for $47.75m 17-Jan-2022 ShareCast
Hikma launches new US injectables unit 10-Jan-2022 ShareCast
Arecor flags milestone payment from Hikma in fir... 21-Dec-2021 ShareCast
Hikma strikes exclusive license agreement with R... 09-Dec-2021 ShareCast
Hikma reports solid trading in year to date 04-Nov-2021 ShareCast
Citi sees room for upside surprise on sales at H... 01-Nov-2021 ShareCast
Hikma buys Custopharm for $375m 27-Sep-2021 ShareCast
Hikma, Bio-Thera enter exclusive agreement for m... 27-Aug-2021 ShareCast
Hikma lifts FY generics guidance as first-half p... 06-Aug-2021 ShareCast
Tuesday broker round-up 08-Jun-2021 ShareCast
Hikma predicts generics revenue at top of guidance 30-Apr-2021 ShareCast
Hikma resumes US launch of 'Advair Diskus' generic 21-Apr-2021 ShareCast
Wednesday broker round-up 31-Mar-2021 ShareCast
Jefferies upgrades Hikma to 'buy' 31-Mar-2021 ShareCast
Friday broker round-up 26-Mar-2021 ShareCast
Talks between Hikma and GlaxoSmithKline fail to ... 11-Mar-2021 ShareCast
Monday broker round-up 01-Feb-2021 ShareCast
Hikma mulls acquisition of GlaxoSmithKline asset... 26-Jan-2021 ShareCast
Hikma temporarily suspends launch of generic Adv... 15-Jan-2021 ShareCast
Hikma rallies as it launches generic version of ... 18-Dec-2020 ShareCast
Wednesday broker round-up 02-Dec-2020 ShareCast
Tuesday broker round-up 24-Nov-2020 ShareCast
Tuesday broker round-up 10-Nov-2020 ShareCast
Hikma raises FY guidance for generics unit follo... 05-Nov-2020 ShareCast
FDA response delays Hikma's generic Advair Diskus 22-Sep-2020 ShareCast
Friday broker round-up 04-Sep-2020 ShareCast
Barclays upgrades Hikma after US court ruling 04-Sep-2020 ShareCast
US court of appeals upholds ruling in favour of ... 03-Sep-2020 ShareCast
Thursday broker round-up 13-Aug-2020 ShareCast
Hikma raises sales guidance as profits rise on C... 07-Aug-2020 ShareCast
Tuesday broker round-up 07-Jul-2020 ShareCast
Hikma Pharmaceuticals slumps as Boehringer Ingel... 23-Jun-2020 ShareCast
Sunday share tips: Hikma Pharmaceuticals, Vinaca... 07-Jun-2020 ShareCast
Hikma gets FDA approval for generic version of '... 22-May-2020 ShareCast

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HIK Market Data

Currency UK Pounds
Share Price 1,966.00p
Change Today 8.00p
% Change 0.41 %
52 Week High 2,205.00
52 Week Low 1,722.00
Volume 14,887
Shares Issued 221.89m
Market Cap £4,362.26m
RiskGrade 125

HIK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
51.18% below the market average51.18% below the market average51.18% below the market average51.18% below the market average51.18% below the market average
21.57% below the sector average21.57% below the sector average21.57% below the sector average21.57% below the sector average21.57% below the sector average
Price Trend
56.56% above the market average56.56% above the market average56.56% above the market average56.56% above the market average56.56% above the market average
69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average
Income
8.95% above the market average8.95% above the market average8.95% above the market average8.95% above the market average8.95% above the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
36.86% below the market average36.86% below the market average36.86% below the market average36.86% below the market average36.86% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 1
Strong Sell 0
Total 11
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

HIK Dividends

  Latest Previous
  Final Interim
Ex-Div 21-Mar-24 10-Aug-23
Paid 03-May-24 15-Sep-23
Amount 47.00¢ 25.00¢

Trades for 17-Jun-2024

Time Volume / Share Price
10:27 72 @ 1,966.00p
10:27 148 @ 1,965.00p
10:27 21 @ 1,965.00p
10:27 6 @ 1,965.00p
10:27 1 @ 1,965.00p

HIK Key Personnel

CEO Riad Mishlawi

Top of Page